Palisade Bio Inc PALI

Healthcare Biotechnology

Palisade Bio, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases. It is engaged in advancing a PALI-2108 for the treatment of IBD, including UC and CD and are researching PALI-1908. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract. UC primarily affects the colon and the rectum. CD can affect any part of the gastrointestinal tract, from the mouth to the anus. PALI-2108 is a prodrug PDE4 inhibitor that operates through a mechanism within colon tissues, targeting the key enzyme phosphodiesterase-4 (PDE4). This enzyme is pivotal in cAMP hydrolysis, and by inhibiting PDE4, intracellular cAMP levels are elevated. This elevation leads to the downregulation of inflammatory cytokines and a reduction in the expression of cell adhesion molecules. By modulating these processes, PALI-2108 prevents the local infiltration and activation of inflammatory cells in the colon tissues.

NDAQ:PALI - Post by User

Palisade Bio Inc

<< Previous

Bullboard Posts

Next >>

Post by whytestockson Feb 08, 2024 11:00pm

62 Views

Post# 35871620

Palisade Bio Announces Formation of Clinical Advisory Board

News; $PALI Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion LeadersBruce Sands, MD, MS., Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai and System Chief, Division of Gastroenterology, Mount Sinai Health System Florian Rieder, MD, Associate Staff in the Department of Gastroenterology, Hepatology, and Nutrition, a...PALI - Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals